Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
British Journal of Dermatology · 2023
DOI: 10.1093/bjd/ljad107 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift British Journal of Dermatology, 2023. Verfasst von Duc Binh Phan und 7 weiteren Autor:innen. Beteiligte Einrichtung: Manchester Centre for Dermatology Research, Northern Care Alliance NHS Foundation Trust, The University of Manchester, Manchester Academic Health Sci…. Hauptthemen laut MEDLINE: Biosimilar Pharmaceuticals, Psoriasis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), University of Manchester, British Association of Dermatologists (BAD).
Abstract (Originalsprache)
Background
Tumour necrosis factor-alpha inhibitors (TNFi) have revolutionized the treatment of moderate-to-severe psoriasis. Following patent expiry of the originator biologics, TNFi biosimilars became available, presenting the opportunity for significant reductions in drug costs.
Objectives
To describe the uptake of TNFi biosimilars for psoriasis treatment in the UK and Ireland.
Methods
This observational cohort study utilizes data from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR), a national pharmacovigilance study register for patients with psoriasis on systemic treatments. We analysed biosimilar uptake trends over time in nine geographical regions of England along with Wales, Scotland, Northern Ireland and the Republic of Ireland. We assessed the incidence of switching to biosimilars in an originator-user cohort (switchers). Patients on originators infliximab, etanercept and adalimumab at the time originator patents expired, entered the cohort on 1 February 2015, August 2015 and October 2018, respectively, and were followed up until 31 October 2021. Trends in biosimilar initiations were assessed in an adalimumab-naïve cohort who started adalimumab between 1 October 2018 and 31 July 2019 (starters). We assessed the associations between patient factors and originator-to-biosimilar switching and biosimilar initiation using a multivariable Cox regression model and a multivariable logistic regression model, respectively.
Results
Included in the originator-user cohort were 4202 patients (209 on infliximab, 742 on etanercept and 3251 on adalimumab). For infliximab, etanercept and adalimumab, respectively, the cumulative incidence of originator-to-biosimilar switching increased with time to 14.8%, 23.6% and 66.6% after 3 years. Across geographical regions, 3-year switching rates varied from 0% to 43.7% for infliximab; from 0% to 40.4% for etanercept; and from 12.5% to 84.3% for adalimumab. Out of the 528 patients included in the adalimumab-naïve cohort, 67.8% started on biosimilars. Originator-to-biosimilar switching and biosimilar initiation were more common in men and in patients who had lower Psoriasis Area and Severity Index at cohort entry.
Conclusions
The uptake of biosimilars increased over time and varied considerably across the UK and Ireland; adalimumab had the highest biosimilar uptake rate compared with that of other TNFi drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Manchester Centre for Dermatology Research, Northern Care Alliance NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, National Institute for Health and Care Research (NIHR) Ma…
- Department of Dermatology, Barts Health NHS Trust and Queen Mary College (University of London), London, UK.
- King's College London and St John's Institute of Dermatology, Guy's & St Thomas' NHS Foundation Trust, London, UK.
- Royal Berkshire NHS Foundation Trust, Reading, UK.
- Centre for Epidemiology Versus Arthritis, The University of Manchester, Manchester, UK.
ORCID-Profile: Duc Binh Phan, Anthony P Bewley, Catherine H Smith, Christopher E M Griffiths, Mark Lunt, Richard B Warren, Zenas Z N Yiu
Förderung
- British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)
- University of Manchester
- British Association of Dermatologists (BAD)
- Psoriasis Association
- NIHR Manchester Biomedical Research Centre
Zitieren
APA
Phan, D. B., Bewley, A. P., Smith, C. H., Mackenzie, T., Griffiths, C. E. M., Lunt, M., Warren, R. B., & Yiu, Z. Z. N. (2023). Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). British Journal of Dermatology. https://doi.org/10.1093/bjd/ljad107
Vancouver
Phan DB, Bewley AP, Smith CH, Mackenzie T, Griffiths CEM, Lunt M, et al. Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR). British Journal of Dermatology. 2023. doi:10.1093/bjd/ljad107
BibTeX
@article{Phan2023,
author = {Phan, Duc Binh and Bewley, Anthony P and Smith, Catherine H and Mackenzie, Teena and Griffiths, Christopher E M and Lunt, Mark and Warren, Richard B and Yiu, Zenas Z N},
title = {Uptake of tumour necrosis factor-alpha inhibitor biosimilars for psoriasis: a drug utilization study from the British Association of Dermatologists Biologic and Immunomodulators Register (BADBIR)},
journal = {British Journal of Dermatology},
year = {2023},
doi = {10.1093/bjd/ljad107}
}
EUVIMED